Newsfeeds - Spark Newswire

2 minute read

FDA
News

Castle Biosciences Says Patients With Uveal Melanoma Tested With DecisionDx-UM Report Gaining Value from Test Results In Study Conducted In Collaboration With Melanoma Research Foundation’s CURE OM Initiative

Today, 2:37 PM

Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced findings from a study that evaluated uveal melanoma (UM) patients' attitudes toward

CSTL

1 minute read

Castle Biosciences Highlights Data Showing Co.’s DecisionDx Ability To Risk-Stratify Patients Will Be Featured As Abstract At American Society Of Clinical Oncology Meeting Jun. 3-7, 2022

By Benzinga Newsdesk

Today, 2:37 PM

Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that an abstract demonstrating the ability of the Company’s

CSTL

2 minute read

FDA
News

TissueCypher Outperforms Pathologist Diagnoses When Predicting Progression In Patients Diagnosed With Barrett’s Esophagus With Low-grade Dysplasia

By Benzinga Newsdesk

Today, 2:37 PM

Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced new study data demonstrating the ability of its TissueCypher® Barrett's

CSTL

1 minute read

Keybanc Maintains Overweight on Castle Biosciences, Lowers Price Target to $40

By Benzinga Newsdesk

Today, 2:37 PM

Keybanc analyst Paul Knight maintains Castle Biosciences (NASDAQ:CSTL) with a Overweight and lowers the price target from $90 to $40.

CSTL

1 minute read

SVB Leerink Maintains Outperform on Castle Biosciences, Lowers Price Target to $45

By Benzinga Newsdesk

Today, 2:37 PM

SVB Leerink analyst Puneet Souda maintains Castle Biosciences (NASDAQ:CSTL) with a Outperform and lowers the price target from $65 to $45.

CSTL

1 minute read

Castle Biosciences Q1 EPS $(0.97) Misses $(0.71) Estimate, Sales $26.90M Beat $25.21M Estimate; Raises Guidance

By Benzinga Newsdesk

Today, 2:37 PM

Castle Biosciences (NASDAQ:CSTL) reported quarterly losses of $(0.97) per share which missed the analyst consensus estimate of $(0.71) by 36.62 percent. This is a 470.59 percent decrease over losses of $(0.17) per share

CSTL

16 minute read

Earnings Scheduled For May 9, 2022

By Benzinga Insights

Today, 2:37 PM

Companies Reporting Before The Bell • Atlantica Sustainable (NASDAQ:AY) is likely to report quarterly loss at $0.08 per share on revenue of $277.90 million.

ACM

2 minute read

News

Castle Biosciences Announces Expanded U.S. Federal Supply Schedule Contract Covering Its Entire Dermatologic Cancer Portfolio Of Tests

By Bill Haddad

Today, 2:37 PM

Castle was first awarded a U.S. Federal Supply Schedule contract in August 2021 for DecisionDx®-Melanoma Castle’s expanded U.S. Federal Supply Schedule contract now includes DecisionDx®-SCC,

CSTL

1 minute read

Castle Biosciences Highlights Will Present Data On Its DecisionDx-Melanoma, -Squamous Cell Carcinoma Products At European Association Of Dermato Oncology Congress Apr. 21-23

By Benzinga Newsdesk

Today, 2:37 PM

Poster presentations to highlight DecisionDx®-Melanoma, DecisionDx®-SCC and Castle’s Comprehensive Diagnostic Offering FRIENDSWOOD, Texas--(BUSINESS WIRE)-- Castle Biosciences, Inc. (NASDAQ:CSTL), a

CSTL

15 minute read

Stocks That Hit 52-Week Lows On Tuesday

By Benzinga Insights

Today, 2:37 PM

On Tuesday, 242 companies hit new 52-week lows.

ACRX